Shuttle Pharmaceuticals Holdings Inc
shuttlepharma.comWhat Do They Do?
Builds AI software that predicts molecular properties and helps pharmaceutical researchers evaluate compounds for early-stage drug discovery.
10-K for FY2025, filed Mar 31, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
Who Are Their Customers?
Molecule.ai is designed for pharmaceutical researchers evaluating molecules in early-stage drug development; it currently has no platform customers.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Sep 24, 2026
−$3.1MView ↗
- ▼ −15% (Loss)
- vs −$3.7M in Q2 FY2025
-
Aug 28, 2026
Nasdaq issued a noncompliance notice over a late quarterly filing
The company had until October 27, 2026 to submit a compliance plan; failure to regain compliance could lead to delisting.
Sources
8-K, filed Aug 28, 2026
The Notice states that the Company has 60 calendar days, or until October 27, 2026, to submit a plan to regain compliance with the Listing…View ↗
-
May 7, 2026
Completed merger with United Dogecoin
United Dogecoin became a wholly owned subsidiary after the merger.
Sources
8-K, filed May 7, 2026
On May 6, 2026 (the “Closing Date”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“Shuttle” or “Acquiror”), completed…View ↗
From cancer drugs to research software
The older report centers on developing radiation sensitizers and immune-response drugs for cancer; the latest report adds Molecule.ai’s molecular discovery software and says the Ropidoxuridine clinical trials are being wound down.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 31, 2026
Loading...
